This article is more than 5 years old. Information may no longer be current.

Inotek initiates dosing in phase 3 trial of trabodenoson for glaucoma

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Inotek Pharmaceuticals has initiated patient dosing in a pivotal phase 3 clinical trial of trabodenoson for the treatment of glaucoma, the company announced in a press release.

The phase 3 MATRx-1 clinical trial of trabodenoson includes 335 patients with primary open-angle glaucoma or ocular hypertension. Patients will receive one of three doses of trabodenoson, and IOP will be measured at four time points at days 14, 28, 42 and 84, the release said.

The primary endpoint of the trial will be the reduction in IOP as compared with a placebo treatment arm.

“If approved, trabodenoson — with its potential for once-daily dosing and a mechanism that may complement currently available glaucoma medications — has potential as a valuable treatment option for physicians managing the IOP of patients with disease,” Rudolf Baumgartner, MD, chief medical officer of Inotek, said in the release.

The company plans for the phase 3 clinical trial to be completed in 2016 with topline results expected in the fourth quarter of 2016.